阻塞性睡眠呼吸暂停综合征与英国全科诊疗人群未来痴呆风险
OSAS与全因痴呆(aHR 1.12,95%CI 1.07-1.17)及血管性痴呆(1.29,95%CI 1.19-1.41)风险升高相关,阿尔茨海默病风险无显著变化(1.07,95%CI 0.99-1.16);接受CPAP治疗者全因痴呆风险与匹配对照相近(0.99,95%CI 0.74-1.32)。
要点
- OSAS与全因痴呆及血管性痴呆风险升高相关,阿尔茨海默病风险未见显著升高。
- 接受CPAP治疗的OSAS患者全因痴呆风险与匹配对照相近。
- OSAS患者认知障碍筛查的临床获益及CPAP对认知的影响尚需进一步研究。
核心结论
- OSAS与全因痴呆和部分亚型(血管性痴呆)风险升高相关,与阿尔茨海默病风险无显著关联。
- 接受CPAP治疗的OSAS患者全因痴呆风险与匹配对照相似。
- 仍需进一步研究OSAS患者认知障碍筛查的临床获益及CPAP对认知下降和痴呆风险的影响。
研究设计与样本
- 数据来自英国临床实践研究数据链(CPRD)2000-2022年,为全国代表性初级保健电子健康记录数据库。
- 采用Cox比例风险回归模型量化全因痴呆、血管性痴呆和阿尔茨海默病的发生风险。
主要发现
- 中位随访4.0年(IQR 1.8-7.5),OSAS组与非OSAS组分别有2802例和6211例发生全因痴呆。
- 粗发病率分别为2.47/1000人年和2.34/1000人年。
- OSAS与全因痴呆风险升高相关(aHR 1.12,95%CI 1.07-1.17)。
- OSAS与血管性痴呆风险升高相关(aHR 1.29,95%CI 1.19-1.41)。
- OSAS与阿尔茨海默病风险无显著关联(aHR 1.07,95%CI 0.99-1.16);接受CPAP者全因痴呆风险与匹配对照相近(0.99,95%CI 0.74-1.32)。
关键数值与推荐
- 全因痴呆:aHR 1.12(95%CI 1.07-1.17)。
- 血管性痴呆:aHR 1.29(95%CI 1.19-1.41)。
- 阿尔茨海默病:aHR 1.07(95%CI 0.99-1.16)。
- CPAP治疗者全因痴呆:aHR 0.99(95%CI 0.74-1.32)。
临床怎么用
- 对OSAS患者应关注认知功能与痴呆风险,尤其是血管性痴呆。
- 可将OSAS视为痴呆风险分层的参考因素之一。
- CPAP对痴呆风险的影响尚不明确,不宜据此作为预防痴呆的依据。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstructive sleep apnoea syndrome (OSAS) has been recognised as a potential risk factor for cognitive decline, yet its precise relationship with dementia remains uncertain. This study aimed to determine the risk of dementia among individuals with and without OSAS. METHODS: Data derived from 2.3 million adults (aged ≥18 years) were extracted from the Clinical Practice Research Datalink (2000-2022), a nationally representative primary care electronic health records database in the UK. 193 600 individuals with OSAS were propensity score-matched to 536 701 individuals without OSAS. Cox proportional hazard regression models were applied to quantify the risk of developing all-cause dementia, vascular dementia and Alzheimer's disease between individuals with and without OSAS. RESULTS: With a median follow-up of 4.0 (IQR 1.8-7.5) years, 2802 and 6211 individuals developed all-cause dementia in those with and without OSAS, corresponding to crude incidence rates of 2.47 and 2.34 per 1000 person-years, respectively. The presence of OSAS was associated with higher risks of all-cause dementia (adjusted HR (aHR) 1.12, 95% CI 1.07 to 1.17), vascular dementia (1.29, 95% CI 1.19 to 1.41) and unchanged risk of Alzheimer's disease (1.07, 95% CI 0.99 to 1.16). Individuals with OSAS who had received continuous positive airway pressure (CPAP) treatment exhibited a similar risk of all-cause dementia as their matched counterparts (0.99, 95% CI 0.74 to 1.32). CONCLUSION: OSAS is associated with higher risks of all-cause dementia and some of its subtypes. Further investigation is needed to investigate the clinical benefits of screening for cognitive impairment in people with OSAS and to further evaluate the impact of CPAP on cognitive decline and dementia risk.
引用
- Wang J, Subramanian A, Cockburn N, et al. Obstructive sleep apnoea syndrome and future risk of dementia among individuals managed in UK general practice. Thorax. 2025. PMID: 39689941. doi:10.1136/thorax-2024-221810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。